NEW YORK, July 28, 2017 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Allergan, Inc. (NYSE:AGN) from February 25, 2014 through April 21, 2014, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Allergan investors under the federal securities laws.
To join the Allergan class action, go to http://rosenlegal.com/cases-1156.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
The class action asserts claims under Sections 14(e), 20A and 20(a) of the Securities Exchange Act of 1934 arising from the 2014 attempted acquisition of Allergan by Valeant and its affiliates. The complaint alleges that certain Defendants traded on material non-public information regarding the proposed acquisition, and as a result, Class members that sold Allergan call options, purchased Allergan put options and/or sold Allergan equity forward contracts during the Class Period did so at prices that did not reflect the material nonpublic information known to Defendants. In this action, Plaintiff seeks an award of damages, and prejudgment interest, to Plaintiff and other Class members.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 29, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1156.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Instagram Outage Disrupts Thousands of U.S. Users
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 



